Use of eribulin and lenvatinib as combination therapy for treatment of cancer
The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
1. A method for treating a subject having or at risk of developing cancer, the method comprising administering to the subject in a cancer treatment regimen (i) eribulin or a pharmaceutically acceptable salt thereof, and (ii) lenvatinib or a pharmaceutically acceptable salt thereof, wherein said cancer is selected from the group consisting of breast cancer, pancreatic cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, endometrial cancer, skin cancer, prostate cancer, brain cancer, head and neck cancer, liver cancer, kidney cancer, bladder cancer, gastric cancer, gastrointestinal cancer, cancer of the blood, cancer of the lymphatic system, thyroid cancer, bone cancer, and fibrosarcoma.
2. The method of claim 1 , wherein said subject is a human patient.
3. The method of claim 1 , wherein said subject is diagnosed with cancer, in treatment for cancer, or in post-therapy recovery from cancer.
4. The method of claim 1 , wherein said cancer is a primary tumor or a metastasis.
5. The method of claim 1 , wherein said cancer is a solid tumor.
6. The method of claim 1 , wherein said skin cancer is melanoma.
7. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof is eribulin mesylate.
8. The method of claim 1 , wherein said lenvatinib or said pharmaceutically acceptable salt thereof is lenvatinib mesylate.
9. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof is administered by intravenous infusion.
10. The method of claim 9 , wherein said intravenous infusion is for about 1 to about 20 minutes.
11. The method of claim 10 , wherein said intravenous infusion is for about 2 to about 5 minutes.
12. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof is administered in an amount in the range of about 0.1 mg/m 2 to about 20 mg/m 2 , or about 1.4 mg/m 2 or 1.1 mg/m 2 .
13. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof is administered once on each of days 1 and 8 of a 21-day cycle.
14. The method of claim 1 , wherein said lenvatinib, or said pharmaceutically acceptable salt thereof, is administered daily.
15. The method of claim 1 , wherein said lenvatinib, or said pharmaceutically acceptable salt thereof, is administered orally.
16. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof, and said lenvatinib, or said pharmaceutically acceptable salt thereof, are administered substantially simultaneously.
17. The method of claim 1 , wherein said cancer of the blood is leukemia.
18. The method of claim 1 , wherein said bone cancer is osteosarcoma.
19. The method of claim 1 , wherein said cancer is breast cancer.
20. The method of claim 1 , wherein said cancer is lung cancer.
21. The method of claim 20 , wherein said lung cancer is non-small cell lung cancer.
22. The method of claim 1 , wherein said lenvatinib, or said pharmaceutically acceptable salt thereof, is administered in an amount in the range of about 0.1 mg to about 100 mg.
23. The method of claim 22 , wherein said lenvatinib, or said pharmaceutically acceptable salt thereof, is administered in an amount in the range of about 4 mg to about 24 mg.
24. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof, and said lenvatinib, or said pharmaceutically acceptable salt thereof, are administered sequentially.
25. The method of claim 1 , wherein said eribulin or said pharmaceutically acceptable salt thereof is administered once on each of days 1 and 8 of a 21-day cycle, and said lenvatinib, or said pharmaceutically acceptable salt thereof, is administered daily.